This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017.
Stakeholders Involved in intranasal therapeutics and drugdelivery domain. Based on our research maximum number of players are located in North America (80%), followed by Europe and Asia-Pacific & RoW (5%, each). Intranasal Therapeutics and DrugDeliverySystems. Our Social Media Platform. Web: [link].
Contract marketing companies support pharmaceutical companies in creating, improving, and maintaining their brand, as well as reducing risk, and ensuring better product placement in the market. Identifying the top commercial dose (non-sterile) companies in contract marketing.
Over the years, applications of exosomes in therapeutics have undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Exosome Service Providers – Current Market Landscape. The market is characterized by a mix of well-established and small firms. Our Social Media Platform.
Innovation S-curve for Internet of Things in the pharmaceutical industry Nanoparticles for drugdelivery is a key innovation A nanoparticle is a small particle ranging in size from 1 to 100 nanometres. Nanoparticles are used as novel drugdeliverysystems to deliver drugs to specific tissues and to provide controlled release therapy.
To boost the profitability of the drug at a later stage in its lifecycle, manufacturers may then consider changing the presentation to prefilled syringes. Thanks to the many benefits associated with this type of packaging, this move can be an effective marketing strategy for differentiating existing products from generic competition.
One such recently approved drugmarketed by Intra-Cellular Therapies was Caplyta (lumateperone) for the treatment of bipolar depression in adults. There is also research being conducted on intracellular drugdelivery molecules to treat CVDs. million lives each year. But that’s not all.
In addition to therapeutics, these complex molecules act as a significant resource in various research applications. Oligonucleotide Synthesis, Modification and Purification Services Market. The post Accelerating Oligonucleotide Demand: A Force Driving The Contract Manufacturing Market appeared first on Blog. Web: [link].
Nano-based deliverysystems are on the rise, as they enable manufacturers to deliver therapeutic agents to specific targeted tissue in a more controlled manner. Data indicates that the global nanopharmaceutical drugsmarket size reached USD 53.85 Billion in 2021 and is expected to reach USD 102.4 Billion in 2030.
The VTT Technical Research Centre of Finland has addressed this issue by developing a fully recyclable, modular ECG patch constructed from VTT’s novel cellulose e-skin material. Aayush Jaiswal, research scientist at VTT said, “Ours is the first nanocellulose-based ECG patch with no plastic additives.
Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them. As a result, novel product development opportunities have emerged and are likely to benefit both drug developers and investors alike.
Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. Over 10,000 articles, indicative of the ongoing research and innovation in this field, have been published in scientific literature. FUTURE EVOLUTION. Web: [link].
Next Generation Complement Therapeutics – Current Market Landscape. The market is characterized by a mix of well-established and small firms. The pipeline features more than 190 next generation complement therapeutics that are either marketed / are currently being evaluated across different phases of development.
Owing to the numerous advantages of oral drugdelivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral protein / peptide therapeutics market is anticipated to witness a significant growth in the coming future. Web: [link].
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. Oligonucleotide Synthesis, Modification and Purification Services Market. Our Social Media Platform. Web: [link].
However, for such a burdensome and highly prevalent sight-threatening eye disorder, the Retinal vein occlusion treatment market has no curative option to offer. Retinal vein occlusion drugmarket. The present market lacks an effective treatment to unblock retinal veins.
In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material. Majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy.
Amidst the current initiatives to develop therapeutic interventions with improved bioavailability, nanoparticles have specifically captured the interest of researchers and drug developers, given their ability to act as drug carriers for complex and highly promising therapeutics. Nanoparticles Contract Manufacturing. Web: [link].
Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. Future Evolution of Biopharmaceutical Excipient Manufacturing Market.
Application of Synthetic mRNA Several studies conducted by healthcare companies and research institutions have demonstrated the potential of mRNA. Additionally, they also require appropriate drugdeliverysystems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases).
By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.
Certain areas where this technology is working hand-in-hand with healthcare are: Unsustainable healthcare systems into sustainable ones Equalizing the relationship between medical professionals and patient Provide cheaper, faster and more effective solutions for diseases. Healthcare Technology Utility in Different Platforms. Nanotechnology.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. The pharmaceutical polymers market is highly fragmented, featuring the presence of established companies, as well as emerging start-ups.
Drugs such as pembrolizumab (Merck’s Keytruda) and nivolumab (Bristol Myers Squibb’s Opdivo) have revolutionized the treatment options for skin cancer. Ongoing research on molecular diagnostics and AI-powered diagnostic tools has helped enhance the early detection and treatment of skin cancer, promising improved patient outcomes.
Conjugation with a Variety of Molecular Conjugates and Labels The combination of the conjugates / labels with molecules ( proteins, peptides, antibodies and small molecules ) is being used abundantly for several applications, ranging from therapeutics and diagnostics to isolation and characterization of drugdeliverysystems.
Amidst the ongoing initiatives to develop therapeutic interventions with improved bioavailability, lipid nanoparticle (LNPs) have specifically attracted the attention of researchers and drug developers. The LNPs can be monitored using various imaging modalities to confirm the delivery of siRNA to the target cells.
Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. In a recent webinar, Dr. Vornov described the history and current progress in targeted CNS therapeutic delivery. Viral Vectors for Gene Delivery to the CNS.
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drugdelivery.
A robust drug patent portfolio is not just an assetit’s a critical tool for success. As companies invest billions in research and development, protecting their innovations through strategic patent management has become more important than ever. This creates a web of protection that’s difficult for competitors to navigate.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content